Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin glargine and acarbose in the treatment of type 2 diabetes mellitus
IRCT201403041774N6Phase 3Completed
- Sponsor
- Physiology Research Center, Kerman University of Medical Sciences
- Start
- Aug 2014
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of insulin glargine and acarbose in type 2 diabetes mellitus (T2DM), sponsored by Physiology Research Center, Kerman University of Medical Sciences. Started Aug 2014; status: completed.
02
Drugs
insulin glargineacarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT201403041774N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201403041774N6.